Save
Malignant benign hematology
ISTH Academy, Michelle Sholzberg, 273413
Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment: An observational cohort study
ISTH Academy, Correspondence |Emilie Chalayer, 273414
The effect of stopping phenprocoumon 5 days preoperatively: A retrospective study
ISTH Academy, Correspondence |Marcel van de Ree, 273415
Fondaparinux in heparin‐induced thrombocytopenia: A decade's worth of clinical experience
ISTH Academy, Correspondence |Marc Schindewolf, 273416
Education needs of nurses in thrombosis and hemostasis: An international, mixed‐methods study
ISTH Academy, Correspondence |Patrice Lazure, 273417
Overcoming barriers to integrating direct oral anticoagulants into existing anticoagulation management services
ISTH Academy, Session Speakers, 273418
Circulating endothelial cells as biomarker for cardiovascular diseases
ISTH Academy, Correspondence |Maura Farinacci, 273419
Measurement of tissue factor activity in extracellular vesicles from human plasma samples
ISTH Academy, Nigel mackman, 273420
Circulating microvesicles in snakebite patients with microangiopathy
ISTH Academy, Anoop Enjeti, 273421
ISSUE INFORMATION
ISTH Academy, Session Speakers, 273422
Evaluation of von Willebrand factor concentrates by platelet adhesion to collagen using an in vitro flow assay
ISTH Academy, Thomas Mckinnon, 273428
Dietary intake of marine n‐3 polyunsaturated fatty acids and future risk of venous thromboembolism
ISTH Academy, Trond Isaksen, 273429
Barriers to integrating direct oral anticoagulants into anticoagulation clinic care: A mixed‐methods study
ISTH Academy, Geoffrey Barnes, 273430
Polyphosphate in thrombosis, hemostasis, and inflammation
ISTH Academy, Correspondence |James H. Morrissey, 273431
Prehospital fresh frozen plasma: Universal life saver or treatment in search of a target population?
ISTH Academy, Michael Makris, 273432
Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery
ISTH Academy, Flora Peyvandi, 273331
Chronic liver injury drives non‐traditional intrahepatic fibrin(ogen) crosslinking via tissue transglutaminase
ISTH Academy, James Luyendyk, 273332
High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor
ISTH Academy, Suzanne Cannegieter, 273333
Fifty years new
ISTH Academy, Session Speakers, 273334
Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one‐stage clotting assays
ISTH Academy, Kenneth Friedman, 273335
Exocytosis of Weibel–Palade bodies: how to unpack a vascular emergency kit
ISTH Academy, Ruben Bierings, 273336
Venous thromboembolism in patients with liver diseases: comment
ISTH Academy, Nicolas Intagliata, 273337
Protease‐activated receptor‐1 impedes prostate and intestinal tumor progression in mice: comment
ISTH Academy, Arnold Spek, 273338
Preventing arteriovenous shunt failure in hemodialysis patients: a population‐based cohort study
ISTH Academy, Hsin‐Hsu Wu, 273339
Corrigendum
ISTH Academy, Session Speakers, 273340
Pharmacokinetics of plasma infusion in congenital thrombotic thrombocytopenic purpura
ISTH Academy, Alice Taylor, 273341
Platelet Shp2 negatively regulates thrombus stability under high shear stress
ISTH Academy, Hu Hu, 273342
Let's cross‐link: diverse functions of the promiscuous cellular transglutaminase factor XIII‐A
ISTH Academy, Nicola Mutch, 273343
A unique phenotype of acquired Glanzmann thrombasthenia due to non‐function‐blocking anti‐αIIbβ3 autoantibodies
ISTH Academy, Hirokazu Kashiwagi, 273344
Erratum
ISTH Academy, Session Speakers, 273345
Suppressing protein Z‐dependent inhibition of factor Xa improves coagulation in hemophilia A
ISTH Academy, sharon smith, 273346
Comparative analysis of marketed factor VIII products: comment
ISTH Academy, Michael Makris, 273347
Comparative analysis of marketed factor VIII products: reply
ISTH Academy, Rachel Weissbrod, 273348
Increased urokinase and consumption of α‐antiplasmin as an explanation for the loss of benefit of tranexamic acid after treatment delay
ISTH Academy, Colin Longstaff, 273349
Novel short peripheral catheter design for prevention of thrombophlebitis
ISTH Academy, Dar Weiss, 273350
Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors
ISTH Academy, Jeffrey Zwicker, 273351
mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors
ISTH Academy, Vladimir Bogdanov, 273352
Targeted inhibition of gut microbiota proteins involved in TMAO production to reduce platelet aggregation and arterial thrombosis: a blueprint for drugging the microbiota in the treatment of cardiometabolic disease?
ISTH Academy, Max Nieuwdorp, 273353
Issue Information
ISTH Academy, Session Speakers, 273354
Venous thromboembolism in patients with liver diseases: reply
ISTH Academy, Alexandr Balan, 273355
Announcements
ISTH Academy, Session Speakers, 273356
Genetic determinants of activity and antigen levels of contact system factors
ISTH Academy, Bob Siegerink, 273357
Defective collagen binding and increased bleeding in a murine model of von Willebrand disease affecting collagen IV binding
ISTH Academy, Veronica Flood, 273358
Factor XII truncation accelerates activation in solution
ISTH Academy, Coen Maas, 273359
Crosslinked clots formed independently of factor XIII and without fibrinogen‐to‐fibrin conversion – is this a liver‐specific phenomenon?
ISTH Academy, Ton Lisman, 273360
What the neighbors say
ISTH Academy, Session Speakers, 273361
Sulodexide in venous disease
ISTH Academy, Brett J. Carroll, 273362
Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI‐deficient plasma in vitro
ISTH Academy, Keiji Nogamimi, 273363
Acquired Thrombocytopenia Course
ISTH Academy, Session Speakers, 234805
Pre-Test
ISTH Academy, Session Speakers, 234804
Targeted sequencing to identify novel genetic risk factors for deep vein thrombosis: a study of 734 genes
ISTH Academy, Frits Rosendaal, 273265
The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism: reply
ISTH Academy, Gualtiero Palareti, 273266
The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism: comment
ISTH Academy, Joshua Brown, 273267
The future of bypassing agents for hemophilia with inhibitors in the era of novel agents
ISTH Academy, Amy Shapiro, 273268
Issue Information
ISTH Academy, Session Speakers, 273269
What the neighbors say
ISTH Academy, Session Speakers, 273270
Determining the minimal clinically important difference for the PEmbQoL questionnaire, a measure of pulmonary embolism‐specific quality of life
ISTH Academy, Arash Akaberi, 273271
Dimeric FcγR ectodomains detect pathogenic anti‐platelet factor 4–heparin antibodies in heparin‐induced thromobocytopenia
ISTH Academy, P. Mark Hogarth, 273272
Management of venous thromboembolism in patients with cancer
ISTH Academy, Manuel Monreal, 273273
Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease
ISTH Academy, Alan Michelson, 273274
Determinants of impaired renal and vascular function are associated with elevated levels of procoagulant factors in the general population: reply
ISTH Academy, Willem Lijfering, 273275
Investigations for fetal and neonatal alloimmune thrombocytopenia: communication from the SSC of the ISTH
ISTH Academy, Rachel Petermann, 273276
The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH
ISTH Academy, Michael Makris, 273277
Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer‐associated venous thromboembolism
ISTH Academy, Neil Zakai, 273278
The protease‐activated receptor 4 Ala120Thr variant alters platelet responsiveness to low‐dose thrombin and protease‐activated receptor 4 desensitization, and is blocked by non‐competitive P2Y inhibition
ISTH Academy, Paul F. Bray, 273279
Ultrasound elastography is useful to distinguish acute and chronic deep vein thrombosis
ISTH Academy, Nicola Mumoli, 273280
Genetic regulation of plasma von Willebrand factor levels in health and disease
ISTH Academy, David Lillicrap, 273281
Clinically relevant differences between assays for von Willebrand factor activity
ISTH Academy, Frank Leebeek, 273282
Oxygen saturation or respiratory rate to improve risk stratification in hemodynamically stable patients with acute pulmonary embolism
ISTH Academy, Cecilia Becattini, 273283
Determinants of impaired renal and vascular function are associated with elevated levels of procoagulant factors in the general population: comment
ISTH Academy, Jian‐Hua Zhu, 273284
ISTH News and Updates: Renew Your Membership Today
ISTH Academy, Session Speakers, 273285
Erratum
ISTH Academy, Session Speakers, 273286
The last post
ISTH Academy, Session Speakers, 273287
Rapid determination of anticoagulating effects of dabigatran in whole blood with rotational thromboelastometry and a thrombin‐based trigger
ISTH Academy, Hakan Wallen, 273288
The antifibrinolytic and anti‐inflammatory effects of multiple doses of oral tranexamic acid in total knee arthroplasty patients: a randomized controlled trial
ISTH Academy, Wei‐Nan Zeng, 273289
Evaluation of unfractionated heparin versus low‐molecular‐weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer
ISTH Academy, Tyree Kiser, 273290
Safety of D‐dimer testing as a stand‐alone test for the exclusion of deep vein thrombosis as compared with other strategies
ISTH Academy, Synne G. Fronas, 273291
Keeping it clean: clot biofilm to wall out bacterial invasion
ISTH Academy, John W. Weisel, 273292
Hemostatic abnormalities in patients with Ehlers–Danlos syndrome
ISTH Academy, Ida Martinelli, 273293
Module 8 - Prophylaxis of Venous Thrombosis
ISTH Academy, Walter Ageno, 234786
The Evolution in CAT treatment: Digesting New DOACs Studies Data
ISTH Academy, Cihan Ay & Marc Carrier, 223428
Module 4: Drug-Induced Thrombocytopenia
ISTH Academy, Dr. Brian Curtis & Dr. Tamam Bakchoul, 234427
Protease‐activated receptor‐1 impedes prostate and intestinal tumor progression in mice
ISTH Academy, Joseph Palumbo, 273294
Issue Information
ISTH Academy, Session Speakers, 273295
The missing heritability of venous thrombosis: what about factor V Leiden heterogeneity?
ISTH Academy, Pierre-Emmanuel Morange, 273296
Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery
ISTH Academy, Ron Mathot, 273297
Protein disulfide isomerase regulation by nitric oxide maintains vascular quiescence and controls thrombus formation
ISTH Academy, Christophe Dubois, 273304
The utility of viscoelastic methods in the prevention and treatment of bleeding and hospital‐associated venous thromboembolism in perioperative care: guidance from the SSC of the ISTH
ISTH Academy, Beverley Hunt, 273305
What the neighbors say
ISTH Academy, Session Speakers, 273306
Large‐scale identification of functional microRNA targeting reveals cooperative regulation of the hemostatic system
ISTH Academy, Sven Danckwardt, 273307
A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A
ISTH Academy, Hermann Eichler, 273308
Enhanced activity of an ADAMTS‐13 variant (R568K/F592Y/R660K/Y661F/Y665F) against platelet agglutination in vitro and in a murine model of acute ischemic stroke
ISTH Academy, kieron south, 273309
High risk of recurrent venous thrombosis in patients with lower‐leg cast immobilization
ISTH Academy, Banne Nemeth, 273310
Glucose metabolism and metabolic flexibility in blood platelets
ISTH Academy, Khalid M. Naseem, 273311
ADAMTS‐13 activity and ischemic heart disease: a Mendelian randomization study
ISTH Academy, C Mary Schooling, 273312
Repeated assessments of physical activity and risk of incident venous thromboembolism
ISTH Academy, Line H. Evensen, 273320
Hereditary angioedema: the plasma contact system out of control: comment
ISTH Academy, M. Triggiani, 273321
Marc Verstraete (1925–2018)
ISTH Academy, Session Speakers, 273322
Re‐evaluation of mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology
ISTH Academy, George J. Broze, 273323
Healthcare utilization in chronic thromboembolic pulmonary hypertension after acute pulmonary embolism
ISTH Academy, Yvonne Maria Ende-Verhaar, 273324

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings